Tumor marker analysis showed that after treatment with the XELOX plus sintilimab regimen, the levels of tumor markers carcinoembryonic antigen, carbohydrate antigen 242, carbohydrate antigen 724, and inflammatory cytokine IL6 in the patient’s serum decreased compared to before treatment, and the observation group combined with FZLZD showed a greater decrease than the control group (P < .05) (Table 7). This evidence concerns the gene CEACAM5 and neoplasm.